| Literature DB >> 34312530 |
Lee A Hugar1, Elizabeth M Wulff-Burchfield2, Gary S Winzelberg3, Bruce L Jacobs4, Benjamin J Davies4.
Abstract
Palliative care - specialized healthcare focused on improving quality of life for patients with serious illnesses - can help urologists to care for patients with unmet symptom, coping and communication needs. Society guidelines from the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend incorporating palliative care into standard oncological care, based on multiple randomized trials demonstrating that it significantly improves physical well-being, patient satisfaction and goal concordant care. Misconceptions regarding the objective and ideal timing of palliative care are common; a key concept is that palliative care and treatments seeking to cure or prolong life are not mutually exclusive. Urologists are well positioned to champion the integration of palliative care into surgical urologic oncology and should be aware of palliative care guidelines, indications for palliative care use and how the field of urologic oncology can adopt best practices.Entities:
Mesh:
Year: 2021 PMID: 34312530 PMCID: PMC8312356 DOI: 10.1038/s41585-021-00491-z
Source DB: PubMed Journal: Nat Rev Urol ISSN: 1759-4812 Impact factor: 14.432
Randomized trials of early incorporation of palliative care into standard oncological care
| Study (country, year) | Design and comparison | Cohort | Intervention and outcomes | Key finding |
|---|---|---|---|---|
| Zimmermann et al.[ | Cluster-randomization of medical oncology clinics; early palliative care team consultation and regular follow-up monitoring versus standard oncological care | Patients with advanced cancer (22% lung, 30% GI, 17% GU, 16% breast, 15% Gyn) | Baseline and 4-monthly survey measuring quality of life (FACIT-Spiritual), symptom severity (QUAL-E), and satisfaction and problems with medical interactions (CARES-MIS) | 85% completed at least one follow-up survey; at 4 months, the adjusted difference between change scores favoured the intervention group; FACIT-Sp: 6.44 (95% CI 2.1–10.8), |
| 228 intervention; 233 control | ||||
| Bakitas et al.[ | Randomized control trial, 1:1 block randomization by cancer type and enrolment site; early versus delayed concurrent palliative care and standard oncological care | Advanced cancer (46% lung, 24% GI, 11% breast, 10% other, 8% GU, 5% haematological) | In-person outpatient palliative care physician consultation, 6 weekly nurse-led phone coaching sessions, monthly phone follow-up monitoring; q3 monthly quality of life (FACIT-palliative care), symptom impact (QUAL-E), mood (CES-D), 1-year survival and resource use (hospital admission and ICU days, ED visits, and chemotherapy use) | 66% completed in-person consultation (early by day 24 and late by day 79 after enrolment). 88% of the intervention group completed three or more coaching sessions, compared with 69% of the control group; no significant difference in quality of life, symptom impact or mood at 2, 6 or 12 months after enrolment or 12, 6 or 3 months prior to death; 53% of the cohort died, 15% fewer intervention patients died at 1 year ( |
| 104 early; 103 delayed | ||||
| Maltoni et al.[ | Multicentre randomized trial, 1:1 block randomization by centre, no blinding; early versus on-demand palliative care | Newly diagnosed metastatic or locally advanced inoperable pancreatic cancer at 21 centres | Consultation within 2–4 weeks of randomization and 2–4-weekly thereafter; control group was seen by palliative care only if the patient, family or oncologist requested a consultation. Health-related quality of life (FACT-Hepatobiliary), mood (HADS), and satisfaction with care | All patients in the trial received at least one palliative care consultation but intervention patients received more consultations (mean 8.9 versus 3.9). Upon analysis, 77% of participants died and there was no difference in survival (38% in the intervention group and 32% in the control group); significantly improved quality of life in the intervention group for hepatobiliary cancer subscale (mean difference of 2.5, |
| 97 early; 89 on-demand | ||||
| Vanbutsele et al.[ | Randomized controlled trial, 1:1 block randomization by treating department; early, systematic palliative care versus usual multidisciplinary standard oncological care | Advanced solid malignancy (38% GI, 17% lung, 10% head and neck, 9% GU, 8% breast, 8% melanoma) | Monthly symptom assessment and incorporation of palliative care into multidisciplinary meetings. Change in overall quality of life from baseline at 12 weeks (EORTC QOL C30 and MQOL), as well as 18 and 24 weeks. Anxiety and depression measured via HADS | By 12 weeks, 89% and 27% of intervention patients had at least one palliative care nurse and one palliative care physician consultation, respectively (compared with 18% and 1% in the usual care arm) but 11% of intervention patients did not have any consultations; at 12 weeks, quality of life was significantly improved in the intervention arm via EORTC QLQ C30 (mean difference 7.6, |
| 92 early systemic; 94 usual | ||||
| Temel et al.[ | Randomized trial, 1:1 randomization stratified by cancer type; early palliative care versus usual oncological care | Incurable cancer (55% lung and 45% non-colorectal GI) | Palliative care consultation within 4 weeks of enrolment and at least monthly follow-up monitoring until death; change in overall quality of life from baseline at 12 weeks. Change in FACT-General (primary end-point), change in depression (PHQ-9) and end of life communication (secondary end points) | The mean number of palliative care visits was 6.5 and 0.9 by 24 weeks for intervention and control patients, respectively; at 12 weeks, quality of life was not significantly improved ( |
| 175 early; 175 usual |
CARES-MIS, Cancer Rehabilitation Evaluation System Medical Interaction Subscale; CES-D, Center for Epidemiologic Studies — Depression scale; ED, emergency department; EORTC QLQ C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items; ES, effect size; ESAS, Edmonton Symptom Assessment Scale; FACIT, Functional Assessment of Chronic Illness Therapy; FACT, Functional Assessment of Cancer Therapy; GI, gastrointestinal; GU, genitourinary; Gyn, gynaecological; HADS, Hospital Anxiety and Depression Scale; ICU, intensive care unit; MQOL, McGill Quality of Life Questionnaire; NS, not significant; PHQ-9, Patient Health Questionaire-9; QUAL-E, Quality of Life at the End of Life.
Fig. 1Evolution of palliative care.
Palliative care began with a hospice tradition that dates back to the medieval period. The modern hospice care movement began in the 1960s, and modern palliative care developed during the following decade. Palliative care, with an emphasis on integration with curative or life-prolonging treatments, continues to evolve, with both death and survivorship as possible outcomes[115].
Fig. 2Tenets of palliative care.
Palliative care is often conflated with hospice care, but importantly differs by its integration or parallel administration with curative or life-prolonging treatments. Hospice is more narrow in scope, applies to a select group of patients at the end of life, and aims to affirm life while enabling a ‘good death’. A useful analogy compares palliative care to a pie and emphasizes that hospice is but a narrow slice of that pie. However, as hospice falls under the general discipline of palliative care these two disciplines share many core principles.
Summary of society palliative care guidelines
| Society | Guideline publication date | Timing | Indications | Patient screening | Initial needs assessment |
|---|---|---|---|---|---|
| ASCO[ | January 2017 and May 2018 | Needs should be addressed at presentation to the oncologist, and early specialist involvement should occur within 8 weeks of an advanced cancer diagnosis | Metastatic or poor prognosis cancer, limited treatment options, estimated survival <12 months, frequent admissions owing to refractory symptoms, functional decline, failure to thrive or complex care requirements | All patients with cancer should be screened at presentation and reassessed at appropriate intervals or as clinically indicated. Screening tools include the NCCN Distress Thermometer, Edmonton Symptom Assessment Scale, Condensed Memorial Symptom Assessment Scale and Brief Pain Inventory | Identify palliative care needs with regard to quality of life and physical, functional, spiritual, psychological and social domains; evaluate basic pain and symptom management; determine patient understanding of illness and prognostic awareness; clarify treatment goals; assess medical literacy and decision-making; and coordinate care with other medical teams |
| NCCN[ | February 2020 | Can begin at cancer diagnosis and be delivered concurrently with life-prolonging therapies | Metastatic solid tumour, uncontrolled symptoms, distress related to diagnosis or therapy, serious comorbid conditions, patient or family request for palliative care, poor performance status (ECOG >2 or KPS <60) or cachexia | All patients with cancer should be screened at presentation and reassessed at appropriate intervals or as clinically indicated. If screening criteria are met, proceed to a comprehensive initial palliative care assessment. If no criteria are present, inform patient of palliative care services and rescreen at next visit | Discuss benefit and burdens of anticancer therapy; define patient/family goals, values, priorities and expectations; evaluate for psychosocial and spiritual distress; evaluate educational, cultural and informational needs; begin with initial symptom management if needed; and determine whether criteria for formal palliative care consultation are met |
| EAU[ | March 2013 | Applicable early in the course of illness in conjunction with life-prolonging therapies and be available throughout a patient’s care pathway | No specific criteria proposed, but early collaboration between the oncologist and palliative care team is emphasized | Assess pain (using the OPQRSTUV mnemonic — Onset, Provocative factors, Quality, Radiation, Severity, Timing, Understanding/impact on patient, and Values), patient’s readiness to accept palliative care and the role they expect it to have in their care | Establish excellent communication (good eye contact, open-ended questioning, responding to patient’s emotions, displaying empathy); assess pain; assess patient knowledge and establish goals of medical care; develop realistic expectations; and develop a treatment plan |
Indications less pertinent to genitourinary malignancies in general are not included in the table. ASCO, American Society of Clinical Oncology; EAU, European Association of Urology; ECOG, Eastern Cooperative Oncology Group; KPS, Karnofsky Performance Status; NCCN, National Comprehensive Cancer Network.
Fig. 3Best case/worst case.
This communication tool is a useful graphical aid that the surgeon can use, particularly when discussing treatment options with patients who are acutely ill or have multiple comorbidities. Use of this framework was first described by Schwarze. “To start, the surgeon names each of the patient’s treatment options and describes … the ‘best case’ outcome, the ‘worst case’ outcome, and what [they believe] is the ‘most likely’ outcome for each treatment. The verbal description of each ‘case’ incorporates rich narrative derived from clinical experience and relevant evidence, and focuses on the story of how the patient might experience an outcome, instead of quoting discrete statistical risks. The surgeon simultaneously draws the pen-and-paper diagram, and under each treatment option […] places a vertical bar. The bar length suggests a range of outcomes and the relative magnitude of difference between the ‘best case’ (star), the ‘worst case’ (box) and the physician’s estimate of the ‘most likely’ outcome (oval). After presenting the tool, the surgeon uses phrases to encourage deliberation such as, ‘what do you think about all of this?’”[116]. CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate (ml/min/1.73 m2); KPS, Karnofsky performance status; PCI, percutaneous coronary intervention; RT, radiotherapy.